Search | Clinical Trials Finder

Conditions: Solid Tumor
Interventions: SMP3124LP; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Denver, Colorado • Celebration, Florida + 5 more

Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions: TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1); Drug · Procedure
Lead sponsor: Ascendis Pharma Oncology Division A/S; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more

Conditions: Protein C Deficiency
Interventions: Protein C Concentrate (Human) Vapor Heated; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 10
States / cities: Los Angeles, California • Denver, Colorado • Fort Carson, Colorado + 7 more

Conditions: Ovarian Cancer, Non-small Cell Lung Cancer
Interventions: TUB-040; Drug
Lead sponsor: Tubulis GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia + 15 more

Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Lung Diseases, Respiratory Distress Syndrome, Newborn, Pulmonary Surfactant, Lung Diseases, Interstitial
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Up to 1 Year
Enrollment: 5,176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Interventions: NUV-1511; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Severe Sepsis
Interventions: Drotrecogin alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more

Conditions: Ovarian Cancer
Interventions: misetionamide (also known as GP-2250); Drug
Lead sponsor: Persevere Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Fairway, Kansas • Boston, Massachusetts + 1 more

Conditions: Ischemic Stroke
Interventions: 3K3A-APC, Placebo; Biological · Drug
Lead sponsor: ZZ Biotech, LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 12 more

Conditions: Protein C Deficiency
Interventions: Protein C Concentrate (Human); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Not listed
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: Phoenix, Arizona • Orange, California • Aurora, Colorado + 9 more

Conditions: Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
Interventions: HWK-007; Drug
Lead sponsor: Whitehawk Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more

Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine; Biological · Drug
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more

Conditions: Protein C Deficiency
Interventions: Protein C Concentrate (Human) Vapor Heated; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 9 more

Conditions: Platinum-resistant Ovarian Cancer
Interventions: Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 72
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Xigris; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 9
States / cities: Fresno, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Lung Inflammation
Interventions: placebo pill and placebo IV, Lovastatin pill and placebo IV, placebo pill and recombinant human activated protein C IV, Endotoxin; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 19 Years to 44 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Platinum-resistant Epithelial Ovarian Cancer
Interventions: Maveropepimut-S, Cyclophosphamide 50mg; Other · Drug
Lead sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Nutrient; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 6 Months
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer
Interventions: DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more

Conditions: Ovarian Cancer
Interventions: Investigator's choice of Chemotherapy, Azenosertib; Drug
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Phoenix, Arizona • Antioch, California • Beverly Hills, California + 8 more

Conditions: Advanced Solid Tumors
Interventions: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 862 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 28
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more

Conditions: Neoplasms, Ovarian
Interventions: MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Sacramento, California • San Francisco, California • Whittier, California + 7 more

Search by objective public record fields.

SMP-3124LP in Adults With Advanced Solid Tumors

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Epidemiology of Surfactant Protein-B Deficiency

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

Safety Evaluation of 3K3A-APC in Ischemic Stroke

Ceprotin Treatment Registry

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Activated Protein C to Treat Acute Lung Injuries

Quantifying Airway Inflammation With Radiologic Tests

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Genetic Regulation of Surfactant Deficiency

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer